Ellington Management Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Ellington Management Group’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-17,822	Closed	-$164K	–	819
2015 Q4	$164K	Buy	+17,822	New	+$149K	0.06%	496
2015 Q3	–	Sell	-33,065	Closed	-$325K	–	1012
2015 Q2	$325K	Buy	+33,065	New	+$301K	0.08%	389
2015 Q1	–	Sell	-48,900	Closed	-$428K	–	910
2014 Q4	$428K	Sell	48,900 -35,500	-42%	-$287K	0.14%	240
2014 Q3	$582K	Buy	+84,400	New	+$506K	0.4%	33
2013 Q3	–	Sell	-13,100	Closed	-$65K	–	1075
2013 Q2	$65K	Buy	+13,100	New	+$62.3K	0.01%	761

Other funds holding SCLN

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellington Management Group's SCLN Position: Q1 2016 in Review

Ellington Management Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2016, closing a stake of 17,822 shares — an estimated $164K sold.

Ellington Management Group first reported a position in SCLN in Q2 2013 and held it in 5 quarters. The position peaked at $582K in Q3 2014. 142 funds tracked by Wall St. Rank hold SCLN as of Q1 2016.

Ellington Management Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
Ellington Management Group sold 17,822 Sciclone Pharmaceuticals Inc shares in Q1 2016, an estimated $164K.
Ellington Management Group first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 5 quarters.
Ellington Management Group's Sciclone Pharmaceuticals Inc position peaked at $582K in Q3 2014.
142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2016.

Based on Ellington Management Group's 13F filing for Q1 2016, filed 16 May 2016.